Bobeck Modjtahedi, MD, highlights some of the challenges of using telehealth to treat individuals with diabetic retinopathy.
For ophthalmology, once it becomes time for an intervention, patients have to come into the clinic in person, said Bobeck Modjtahedi, MD, a vitreoretinal surgeon at Kaiser Permanente in Southern California.
Transcript
What are the limitations of telehealth when it comes to treating patients with diabetic retinopathy?
I will say that one of the benefits of telehealth is that, one of the things that we have found in our research is that a barrier to care is oftentimes patients have difficulty coming in during work hours because they're afraid of missing work, and especially during economic anxiety times. The telehealth option opens up more appointments for them, like from 5 o'clock at night to 7 o'clock at night, for example, to come in to get photographs, or even on Saturdays. The limitation is that once someone actually needs intervention, then that becomes a problem. Then they're more constrained within what can be done within regular work hours. Those patients who are used to doing after-hours visits now have to readjust and come in during regular business hours. Obviously, we're very good at screening.
We obviously can't give treatment. Unlike, potentially, telehealth models that rely on systemic management of pills or you can call a patient [and]tell them to adjust their blood pressure medication or pick something up in a pharmacy, for ophthalmology, once it comes time for intervention, the patients have to come to the clinic and get injections or lasers. It's something that's very procedurally and interventionly heavy. Once you're at the treatment stage, we're out of the period where telehealth can really work for ophthalmology purposes. The main benefit for tele-ophthalmology is screening those patients that have relatively low-risk conditions, but who are still in a place where they require high clinic resources. So lots of pictures and lots of monitoring. For that, we really excel. But once you're in the interventional stage, like I mentioned, you're committed to being seen in person at that point.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More
Bimekizumab Poised to Tackle Unmet HS Treatment Needs
October 18th 2024Hidradenitis suppurativa (HS) is an inflammatory, chronic disease with very high symptom and physical burdens, and it can get progressively worse over time if it's inadequately treated, explained Amit Garg, MD, founding chair, Department of Dermatology, Northwell Health.
Read More